Genome editing or genome engineering is the technique that enables scientists to make modifications in an individual’s DNA. This also includes alterations in different organisms, such as bacteria, plants, and the animals. DNA editing result in changes in the physical attributes, such as color of eyes, disease risk, and more. Today, scientists are making use of various technologies to execute this process. Presently, the CRISPR technology is trending across the globe in the genome engineering field. Researchers more often make use of this improved and highly efficient technology, CRISPR to control the genome to learn the gene functionality. Nonetheless, the latest improvements in the field of gene editing technology have indicated it to be the most promising and therapeutic means also.
Genome Editing/Genome Engineering Market was valued at over US$ 3.0 Bn. in 2017 and is anticipated to grow at a CAGR of 14.1% from 2019 to 2030.
The growth of this market can be attributed to the major factor that is utilization of the technique for therapeutic genetic editing in infected tissues and cells, thereby reducing the mutations.
Major Key Players of the Genome Editing/Genome Engineering Market are:
Thermo Fisher Scientific, Lonza, Merck, Horizon Discovery Group, Integrated DNA Technologies, New England Biolabs (US), GenScript (US), Sangamo BioSciences (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland)., among others.
No comments:
Post a Comment